1. P.016 Reduction in migraine-associated burden over 24 weeks of treatment with eptinezumab in patients with chronic migraine. (June 2022) Authors: McAllister, P; Kudrow, D; Cady, R; Hirman, J; Ettrup, A; Minhas, S Journal: Canadian journal of neurological sciences Issue: Volume 49(2022)Supplement 1 Page Start: S11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P.032 Long-term safety and tolerability of eptinezumab in patients with chronic migraine: A 2-year, open-label, phase 3 trial. (November 2021) Authors: Kudrow, D; Cady, R; Allan, B; Pederson, S; Hirman, J; Meessen-Pinard, M; Schaeffler, B Journal: Canadian journal of neurological sciences Issue: Volume 48(2021)Supplement S3 Page Start: S29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗